Conference Coverage

Selecting the Right Oral MS Drug


 

References

Upcoming Oral Agents
The investigational oral agent furthest along in the developmental pipeline is laquinimod, a quinolone-3-carboxamide small molecule for which two phase III clinical trials have been completed. The European Medicines Agency is reviewing the drug for marketing approval. Teva, the drug’s manufacturer, has not yet applied to the FDA for approval in the United States.

Several second-generation sphingosine-1-phosphate agonists are in development. They are believed to act more selectively, and thus to entail a lower risk of compromising the immune system, than fingolimod. These agents include siponimod, ponesimod, and ONO-4641.

—Bruce Jancin
IMNG Medical News

Pages

Recommended Reading

Mark Freedman, MD
ICYMI Multiple Sclerosis
Anti-JCV Antibody Index May Further Define PML Risk
ICYMI Multiple Sclerosis
Fingolimod Slows MS Brain Atrophy Within Six Months
ICYMI Multiple Sclerosis
Simvastatin May Reduce Brain Atrophy in Patients With Secondary Progressive MS
ICYMI Multiple Sclerosis
Monoclonal Antibodies Could Become Popular Treatments for MS
ICYMI Multiple Sclerosis
New and Noteworthy Information—August 2013
ICYMI Multiple Sclerosis
Recommendations Outline How to Improve Dimethyl Fumarate Tolerability in MS
ICYMI Multiple Sclerosis
Heart Effects of Fingolimod May Resolve Within Six Hours
ICYMI Multiple Sclerosis
New and Noteworthy Information—September 2013
ICYMI Multiple Sclerosis
Investigating the Links Between MS Drugs, Autoimmune Disease, and Disease Progression
ICYMI Multiple Sclerosis